This trial is testing a new cancer drug, PT-112. It is in two parts, the first of which has finished enrolling. The second part is testing PT-112's safety and how well it works in patients with thymoma or thymic carcinoma, and in patients with metastatic castrate-resistant prostate cancer.
5 Primary · 11 Secondary · Reporting Duration: up to 24 months
180 Total Participants · 3 Treatment Groups
Primary Treatment: PT-112 Injection · No Placebo Group · Phase 2
Age 18+ · Male Participants · 7 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: